title: [Lasting treatment of facial HIV and non HIV lipoatrophies through the use of SAM GoreTex malar implants and polyacrylamide hydrogel filler Eutrophill. About 90 consecutive cases].
abstract: HIV-related lipoatrophy (HIV LA) stands out with regard to its recent discovery, increasing incidence, multiple etiologies, relatively low morbidity, apparently irreversible effects, and unequivocal clinical features. The underlying cause of HIVLA is still controversial but there is an increasing demand of correction. We describe a technique using soft malar implants and acrylamid gel injections separately or in combination. Expanded polytetrafluoroethylene (Gore SAM) malar implants are used for augmentation of the most sunken areas below the eye; they should be placed subperiostealy and more medially than conventional implants. After trying sheets and custom made implants, preshaped GoreTex) Sam implants are now used systematicaly. Eutrophill) is a 2.5% polyacrylamide hydrogel obtained by polymerization of acrylamide monomers with an official half-life of 5 years. The soluable chains are more or less slowly released by enzymatic degradation and subsequently cleared via interstitial tissue without further metabolism or degradation. Injection should be performed continuously and evenly from one side to the other in the deepest part of the sunken area at the subcutaneous level only. A total of 90 consecutive patients were treated using implants alone in 11 cases, injections alone in 68 cases, and both implants and injections in 11 cases. Drawbacks were very few except three cases of chronic inflammation (dental conflict) with sheets and custom made implants which were never observed since the use of preshaped forms, and some very light bulgings with acrylamid injections which usually desapear in a few months. Mean follow-up was 17 months for injections and 29 for implants.
authors.affiliation: mole@cegetel.net
authors.forename: B
authors.initials: B
authors.lastname: Môle
mesh_terms: D000180:Acrylic Resins / Q000627:therapeutic use*; D000273:Adipose Tissue / Q000473:pathology* / Q000601:surgery*; D000328:Adult; D000368:Aged; D001284:Atrophy / Q000209:etiology / Q000473:pathology / Q000601:surgery; D016022:Case-Control Studies; D005146:Facial Asymmetry; D015658:HIV Infections / Q000150:complications*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011138:Polytetrafluoroethylene / Q000627:therapeutic use*; D019736:Prostheses and Implants; D019651:Plastic Surgery Procedures / Q000379:methods* / Q000706:statistics & numerical data*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000180:Acrylic Resins; C016680:polyacrylamide gels; D011138:Polytetrafluoroethylene